Companies: โ€”ยทtotal market cap: โ€”
$ USD
companiesbycap
Menu
Global rankingSuperinvestorsHeatmap
Countries
๐Ÿ‡บ๐Ÿ‡ธUnited States๐Ÿ‡จ๐Ÿ‡ฆCanada๐Ÿ‡ฉ๐Ÿ‡ชGermany๐Ÿ‡ซ๐Ÿ‡ทFrance๐Ÿ‡ฌ๐Ÿ‡งUnited Kingdom๐Ÿ‡จ๐Ÿ‡ญSwitzerland๐Ÿ‡ฎ๐Ÿ‡ณIndia๐Ÿ‡ฏ๐Ÿ‡ตJapan
Categories
๐Ÿ’ปTechnology๐ŸฆFinancials๐Ÿ’ŠHealthcare๐Ÿ›๏ธConsumer Cyclical๐Ÿ“กCommunication๐ŸญIndustrials๐Ÿ›’Consumer DefensiveโšกEnergy
ESPR
Esperion Therapeutics Inc. ESPR
$3.15
โ–ฒ +0.00% 24H
0.7728.6656.5584.44112.332013-062016-092019-122023-032026-06

About

Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), whichโ€ฆ

SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees294
TickerESPR

Statistics

Market Cap$812.1M
Revenue (TTM)$403.1M
Net Income-$22.7M
Net Margin-5.6%
EPS$-0.11
P/E-28.59
P/S1.94
P/B-2.57
EV/EBITDA15.76
ROE7.5%
Dividend Yieldโ€”
Price$3.15

Data: Twelve Data ยท Revenue = mcap / P/S

Esperion Therapeutics Inc. (ESPR) โ€” Market Cap, Revenue, Net Income, P/E | companiesbycap